The verdict
Our read at a glance.
Whether uroguanylin and its analogs do what they are used and marketed for, which ranges from approved treatment of constipation to unproven appetite and metabolic claims.
- The signal
- The uroguanylin analog plecanatide has randomized trials and FDA approval for chronic idiopathic constipation and constipation-predominant irritable bowel syndrome, where it improves bowel symptoms. Evidence that uroguanylin or its analogs help appetite, weight, or metabolic health in people is preliminary and not established.
- The unknown
- Whether targeting this pathway does anything useful beyond the gut, such as for appetite or metabolism, which has not been shown in people.
- Our read
- A real, approved gut-drug target with a proven analog for constipation, and a much weaker story for everything else. Plecanatide works for specific bowel conditions, but uroguanylin marketed for weight or metabolism is unproven.
The mechanism
How it works.
Uroguanylin is a natural gut hormone that binds the guanylate cyclase-C receptor lining the intestine. Binding raises the signaling molecule cyclic GMP inside intestinal cells, which drives fluid and chloride secretion into the gut and speeds transit, which is what relieves constipation. The FDA-approved analog plecanatide mimics uroguanylin to do exactly this. The same receptor and cyclic GMP signaling also reach nerves involved in appetite and abdominal sensation, so the pathway is studied beyond constipation, but those uses are not established in people.
Safety & regulatory boundary
The consequential part.
The only approved uroguanylin-pathway drug is plecanatide, for specific bowel conditions, and it carries a boxed warning against use in young children because of dehydration risk seen in animals. Uroguanylin sold as a standalone peptide product for weight loss or metabolic benefit is not an approved medicine, is unproven for those uses, and products of uncertain identity and purity should not be treated as equivalent to the approved drug.
What's next
What we're watching.
Whether any controlled human trial tests uroguanylin-pathway drugs for appetite, weight, or metabolic outcomes rather than bowel function.
Context
Why this is discussed.
The guanylate cyclase-C pathway is a proven drug target for constipation, and uroguanylin's role in appetite has drawn interest in whether it could matter for weight.
The evidence base
21 cited references.
Regulatory & labels1
Salix Pharmaceuticals Inc. (FDA label) · 2024
Registered trials8
ClinicalTrials.gov · PHASE1 · COMPLETED · 2022-11-30
ClinicalTrials.gov · PHASE2 · COMPLETED · 2018-06-30
ClinicalTrials.gov · PHASE3 · COMPLETED · 2022-03-18
ClinicalTrials.gov · PHASE3 · COMPLETED · 2016-01
ClinicalTrials.gov · PHASE2 · COMPLETED · 2010-03
ClinicalTrials.gov · PHASE3 · COMPLETED · 2013-11
ClinicalTrials.gov · COMPLETED · 2018-06-21
ClinicalTrials.gov · PHASE2 · COMPLETED · 2017-01
Indexed literature (PubMed)12
Lacy BE et al. · Am J Gastroenterol · 2021
PubMed · 2012
Nardone M et al. · Nephrol Dial Transplant · 2025
Rao SSC · Ther Adv Gastroenterol · 2018
Dunn ME et al. · Nature · 2024
Leung K · 2004
Brancale A et al. · Pharmacol Res Perspect · 2017
Wei JQ et al. · Cardiovasc Res · 2025
Chang WL et al. · World J Gastrointest Pharmacol Ther · 2017
Al-Salama ZT et al. · Drugs · 2017
PubMed · 2012
Kalola UK et al. · 2026
Keep reading